In 2015 the U.S. Food and Drug Administration (FDA) approved four new agents for the treatment of relapsed or refractory MM. In February, the FDA approved panobinostat (Farydak), the first histone deacetylase (HDAC) inhibitor to receive FDA approval. In November, the FDA accelerated the approval of daratumumab (Darzalex), the first-ever monoclonal antibody and immunotherapy for MM. In December, the second monoclonal antibody and immunotherapy option, elotuzumab (Empliciti), received FDA approval. Finally, ixazomib (Ninlaro), the fourth drug for MM and first oral proteasome inhibitor, was approved. In this session we will discuss the mechanism of action and adverse-event profile for each of these new agents.
Content Area: Patient Management & Therapeutics